Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?

Toshiyuki Yonezawa, Atsushi Suzuki, Kensuke Fukumitsu, Takuma Katano, Hisashi Kako, Makoto Ishii, Akio Niimi, Kazuyoshi Imaizumi, Koji Sakamoto, Norihito Omote, Etsuro Yamaguchi

研究成果: ジャーナルへの寄稿学術論文査読

抄録

We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.

本文言語英語
論文番号101857
ジャーナルRespiratory Medicine Case Reports
43
DOI
出版ステータス出版済み - 01-2023

All Science Journal Classification (ASJC) codes

  • 呼吸器内科

フィンガープリント

「Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル